Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 172
Filtrer
1.
Urolithiasis ; 52(1): 25, 2024 Jan 10.
Article de Anglais | MEDLINE | ID: mdl-38197964

RÉSUMÉ

Extrapolations from the adult population have suggested that opioids should be avoided in the management of pediatric urolithiasis, but the literature is sparse with regards to actual practice patterns and the downstream implications. We sought to investigate the rate of oral opioid administration for children presenting to the emergency room (ER) with urolithiasis and to identify associations between opioid administration and return visits and persistent opioid use. The TriNetX Research and Diamond Networks were used for retrospective exploratory and validation analyses, respectively. Patients <18 years presenting to the emergency room with urolithiasis were stratified by the receipt of oral opioids. Propensity score matching was performed in a 1:1 fashion. Incident cases of opioid administration and risk ratios (RRs) for a return ER visit within 14 days and the presence of an opioid prescription at 6 to 12 months were calculated. Of the 4672 patients in the exploratory cohort, 11.9% were prescribed oral opioids. Matching yielded a total of 1084 patients. Opioids at the index visit were associated with an increased risk of return visits (RR 1.51, 95% CI 1.04-2.20, P = 0.03) and persistent opioid use (RR 4.00, 95% CI 2.20-7.26, P < 0.001). The validation cohort included 6524 patients, of whom 5.7% were prescribed oral opioids. Matching yielded a total of 722 patients and demonstrated that opioids were associated with an increased risk of return visits (RR 1.50, 95% CI 1.04-2.16, P = 0.03) but not persistent opioid use (RR 1.70, 95% CI 0.79-3.67, P = 0.17). We find that the opioid administration rate for pediatric urolithiasis appears reassuringly low and that opioids are associated with a greater risk of return visits and persistent use.


Sujet(s)
Analgésiques morphiniques , Urolithiase , Adulte , Humains , Enfant , Analgésiques morphiniques/effets indésirables , Études rétrospectives , Service hospitalier d'urgences , Ordonnances , Urolithiase/traitement médicamenteux , Urolithiase/épidémiologie
2.
J Endourol ; 37(8): 921-927, 2023 08.
Article de Anglais | MEDLINE | ID: mdl-37288746

RÉSUMÉ

Introduction: We sought to examine the practice patterns of pain management in the emergency room (ER) for renal colic and the impact of opioid prescriptions on return ER visits and persistent opioid use. Methods: TriNetX is a collaborative research enterprise that collects real-time data from multiple health care organizations within the United States. The Research Network obtains data from electronic medical records and the Diamond Network provides claims data. We queried the Research Network for adults who visited the ER for urolithiasis, stratified by receipt of oral opioid prescriptions, to calculate the risk ratio (RR) of patients returning to the ER within 14 days and persistent opioid use ≥6 months from the initial visit. Propensity score matching was performed to control for confounders. The analysis was repeated in the Diamond Network as a validation cohort. Results: There were 255,447 patients in the research network who visited the ER for urolithiasis, of whom 75,405 (29.5%) were prescribed oral opioids. Black patients were less likely to receive opioid prescriptions than other races (p < 0.001). After propensity score matching, patients who were prescribed opioids had an increased risk of a return ER visit (RR 1.25, confidence interval [95% CI] 1.22-1.29, p < 0.001) and persistent opioid use (RR 1.12, 95% CI 1.11-1.14, p < 0.001) compared with patients who were not prescribed opioids. These findings were confirmed in the validation cohort. Conclusions: A significant proportion of patients presenting to the ER for urolithiasis receive opioid prescriptions, which carries a markedly increased risk of return ER visits and long-term opioid use.


Sujet(s)
Troubles liés aux opiacés , Colique néphrétique , Urolithiase , Adulte , Humains , États-Unis , Analgésiques morphiniques/effets indésirables , Colique néphrétique/traitement médicamenteux , Ordonnances , Types de pratiques des médecins
3.
J Endourol ; 37(1): 119-122, 2023 01.
Article de Anglais | MEDLINE | ID: mdl-36103379

RÉSUMÉ

Introduction: Patients who form kidney stones are typically advised to limit intake of nondairy animal protein. Plant-based meat products may be a processed substitute protein source for these patients and have recently gained popularity because of health concerns, increased retail availability, decreased environmental impact, and meat supply shortages during the COVID-19 pandemic. Despite these perceived benefits and tangential association with whole food plant-based diets, the potential lithogenic risks associated with these products are not well characterized. Methods: The U.S. Department of Agriculture database was queried with a sample of plant-based meat products widely available to U.S. consumers. Nutrient profile data were compiled and compared with animal protein data using standardized serving sizes. Primary protein sources were identified using verified ingredient lists. Oxalate content was extrapolated based on dietary data sources. Results: A total 47 plant-based meat products (16 beef, 11 pork, 10 chicken, and 10 seafood) were analyzed. Compared with their respective animal protein, most products contained on average fewer calories (plant-based beef 77%, pork 94%, chicken 86%, and seafood 83%) and less protein (plant-based beef 68%, pork 96%, chicken 53%, and seafood 54%). Most products used soy protein as the primary protein source (55%). Soy-based beef contained the highest average oxalate content (18 mg per serving), whereas soy-based seafood contained the lowest (7 mg). The most common non-soy protein source was pea protein (30%), containing trace amounts of oxalate. Sodium content was higher in most plant-based products overall (72%) and in each category (plant-based beef 109%, pork 128%, chicken 100%, and seafood 148%). Calcium content was higher (plant-based beef 317%, pork 144%, chicken 291%, and seafood 295%) compared with animal protein. Conclusions: Most plant-based meat products consist of protein sources that are, relative to animal protein sources, higher in oxalate, sodium, and calcium. Stone-forming patients should be counseled about the potential lithogenic risk of these processed products.


Sujet(s)
COVID-19 , Produits carnés , Animaux , Bovins , Humains , Calcium , Poulets , Viande , Évaluation de l'état nutritionnel , Oxalates , Pandémies
4.
BJU Int ; 131(5): 617-622, 2023 05.
Article de Anglais | MEDLINE | ID: mdl-36515438

RÉSUMÉ

OBJECTIVES: To compare the carbon footprint and environmental impact of single-use and reusable flexible cystoscopes. MATERIALS AND METHODS: We analysed the expected clinical lifecycle of single-use (Ambu aScope™ 4 Cysto) and reusable (Olympus CYF-V2) flexible cystoscopes, from manufacture to disposal. Performance data on cumulative procedures between repairs and before decommissioning were derived from a high-volume multispecialty practice. We estimated carbon expenditures per-case using published data on endoscope manufacturing, energy consumption during transportation and reprocessing, and solid waste disposal. RESULTS: A fleet of 16 reusable cystoscopes in service for up to 135 months averaged 207 cases between repairs and 3920 cases per lifecycle. Based on a manufacturing carbon footprint of 11.49 kg CO2 /kg device for reusable flexible endoscopes and 8.54 kg CO2 /kg device for single-use endoscopes, the per-case manufacturing cost was 1.37 kg CO2 for single-use devices and 0.0017 kg CO2 for reusable devices. The solid mass of single-use and reusable devices was 0.16 and 0.57 kg, respectively. For reusable devices, the energy consumption of reusable device reprocessing using an automated endoscope reprocessor was 0.20 kg CO2 , and per-case costs of device repackaging and repair were 0.005 and 0.02 kg CO2 , respectively. The total estimated per-case carbon footprint of single-use and reusable devices was 2.40 and 0.53 kg CO2 , respectively, favouring reusable devices. CONCLUSION: In this lifecycle analysis, the environmental impact of reusable flexible cystoscopes is markedly less than single-use cystoscopes. The primary contributor to the per-case carbon cost of reusable devices is energy consumption of reprocessing.


Sujet(s)
Dioxyde de carbone , Cystoscopes , Humains , Cystoscopie/méthodes , Empreinte carbone , Dépenses de santé
5.
Int Urol Nephrol ; 54(11): 2797-2803, 2022 Nov.
Article de Anglais | MEDLINE | ID: mdl-35906501

RÉSUMÉ

PURPOSE: With the ubiquity of lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH) in older men, costs related to this highly prevalent disease are likely significant but not well defined. With this study, we hoped to define costs related to LUTS/BPH care. METHODS: We utilized the Optum© de-identified Clinformatics® Data Mart Database (CDM) for privately insured male enrollees aged 40-64 years with LUTS/BPH (N ≈ 100,300 annually) and the Centers for Medicare and Medicaid Services Medicare 5% Sample for male beneficiaries aged 65 + years with LUTS/BPH (N ≈ 147,800 annually). Annual LUTS/BPH-related expenditures from 2004 to 2013 were age standardized and calculated overall and by age and service location. RESULTS: The Medicare cohort demonstrated a 23% increase in total costs over the study period with a 28% decrease in CDM costs. Decreases in inpatient hospital charges (45% for Medicare, 55% for CDM) were offset by increasing hospital-based outpatient fees (120% for Medicare, 87% for CDM). Overall, we estimated a total cost of at least $1.9 billion for treatment of men with LUTS/BPH for 2013. Per person expenditures increased with age within cohorts with an average per-person cost of $269 (CDM) and $248 (Medicare) in 2013. CONCLUSION: The distribution of healthcare expenditures for LUTS/BPH shifted across practice settings from 2004 to 2013, with increasing outpatient relative to inpatient expenditures. Total direct costs for LUTS/BPH in 2013 were at least $1.9 billion, not accounting for indirect costs or certain unmeasured populations.


Sujet(s)
Symptômes de l'appareil urinaire inférieur , Hyperplasie de la prostate , Sujet âgé , Études de cohortes , Coûts des soins de santé , Humains , Symptômes de l'appareil urinaire inférieur/étiologie , Symptômes de l'appareil urinaire inférieur/thérapie , Mâle , Medicare (USA) , Hyperplasie de la prostate/diagnostic , États-Unis
6.
J Endourol ; 36(9): 1243-1248, 2022 09.
Article de Anglais | MEDLINE | ID: mdl-35383481

RÉSUMÉ

Background: Higher temperatures have been associated with increased stone formation and subsequent utilization of hospital resources, including inpatient admission. However, these observations have been derived from the adult population. We sought to examine if this purported association extends to the pediatric population. Methods: We used the 2016 Kids' Inpatient Database to identify nationwide pediatric inpatient admissions related to nephrolithiasis. Temperature data from the National Oceanic and Atmospheric Administration was linked to each admission. Comparative statistics analyzed patient and admission characteristics. Multivariable logistic regression analyzed associations between stone-related admissions and temperature. As a frame of reference, this analysis was replicated using the National Inpatient Sample from 2016 to evaluate associations in the adult population. Results: Of the 2,496,257 pediatric admissions, 8453 (0.33%) were related to nephrolithiasis. Temperatures at the time of stone admission were higher than those during nonstone admission (55.9°F vs 54.8°F, p < 0.001). The stone admission group had a higher proportion of females than the nonstone admission group (64.8% vs 55.4%, p < 0.001). Stone admission was significantly associated with temperature (odds ratio [OR] 1.025 per 10°F, confidence interval [95% CI] 1.003-1.049, p = 0.03) and female gender (OR 1.097, 95% CI 1.027-1.171, p = 0.006). In the adult population, 380,520 out of 30,000,941 patients (1.3%) were admitted with a stone. The effect of temperature on stone admissions was similar to that in the pediatric population (OR 1.020, 95% CI 1.014-1.026, p < 0.001), but women were >20% less likely to be admitted for stones than men (OR 0.770, 95% CI 0.757-0.784, p < 0.001). Conclusions: Increased temperatures were associated with an increased risk of stone-related admission in both the pediatric and adult populations. Females were at increased risk for stone-related admissions during childhood, but this trend reverses in adulthood.


Sujet(s)
Patients hospitalisés , Calculs rénaux , Adulte , Enfant , Bases de données factuelles , Femelle , Hospitalisation , Humains , Calculs rénaux/épidémiologie , Mâle , Température
7.
Prostate Cancer Prostatic Dis ; 25(2): 269-273, 2022 02.
Article de Anglais | MEDLINE | ID: mdl-34545201

RÉSUMÉ

BACKGROUND: The American Urological Association makes recommendations for evaluation and testing for lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) to help primary care providers and specialists identify LUTS/BPH and harmful related conditions including urinary retention and prostate or bladder cancer. Our understanding of provider adherence to these Guidelines is limited to single-site or nonrepresentative settings. METHODS: We analyzed two insurance claims databases: the Optum® de-identified Clinformatics® Data Mart database for privately insured males aged 40-64 years (N ≈ 1,650,900 annually) and the Medicare 5% Sample for males aged ≥65 years (N ≈ 546,000 annually). We calculated the annual prevalence of LUTS/BPH and comorbid bladder cancer and bladder stones from 2004 to 2013. We additionally examined LUTS/BPH incidence and adherence to testing guidelines in a cohort of men newly diagnosed with LUTS/BPH in 2009. RESULTS: While LUTS/BPH prevalence and incidence increased with increasing age, evaluation testing became less common. Urinalysis was the most common testing type but was performed in <60% of incident patients. Serum prostate-specific antigen (PSA) was the second most common test across age groups (range: 15-34%). Prevalence of comorbid bladder cancer (range: 0-4%), but not bladder stones (range: 1-2%), increased with increasing age. CONCLUSIONS: Although older men were at greater risk of LUTS/BPH than younger men, they were less likely to undergo testing at diagnosis. Recommended testing with urinalysis was poor despite higher prevalence of bladder cancer in older men and a standard recommendation for urinalysis since 1994. Providers should be more cognizant of AUA Guidelines when assessing LUTS/BPH patients.


Sujet(s)
Symptômes de l'appareil urinaire inférieur , Hyperplasie de la prostate , Tumeurs de la prostate , Tumeurs de la vessie urinaire , Sujet âgé , Adhésion aux directives , Humains , Symptômes de l'appareil urinaire inférieur/diagnostic , Symptômes de l'appareil urinaire inférieur/épidémiologie , Symptômes de l'appareil urinaire inférieur/étiologie , Mâle , Medicare (USA) , Hyperplasie de la prostate/complications , Hyperplasie de la prostate/diagnostic , Hyperplasie de la prostate/épidémiologie , Tumeurs de la prostate/complications , Tumeurs de la prostate/diagnostic , Tumeurs de la prostate/épidémiologie , États-Unis/épidémiologie
8.
J Endourol ; 36(1): 38-46, 2022 01.
Article de Anglais | MEDLINE | ID: mdl-34314232

RÉSUMÉ

Introduction: Multimodal analgesic regimens incorporating peripheral nerve blocks (PNBs) have demonstrated reduced postoperative pain, opioid use, and recovery time in various disease states. However, this remains a subject of limited investigation in the percutaneous nephrolithotomy (PCNL) domain. In the face of an ongoing opioid epidemic and collective push to enhance prescribing stewardship, we sought to examine the potential opioid-sparing effect of PNBs in PCNL. Methods: A systematic review of Embase and PubMed was performed to identify all randomized controlled trials evaluating the use of a PNB with general anesthesia (GA) vs GA alone for pain control following PCNL. Studies evaluating neuraxial (epidural and spinal) anesthesia and those without GA as the control arm were excluded. Results: Seventeen trials evaluating 1,012 procedures were included. Five different blocks were identified and evaluated: paravertebral (n = 8), intercostal nerve (n = 3), quadratus lumborum (n = 2), transversus abdominis plane (n = 1), and erector spinae (n = 3). Nine of 16 (56%) studies observed lower pain scores with PNB use throughout the 24-hour postop period. By comparison, improved pain scores with PNBs were limited to the early (<6 hours) recovery period in five studies and two found no difference. Total analgesic and opioid requirements were significantly higher in the GA control arm in nearly all studies (12/14, 86%). Operative times were similar and there were no differences in rates of intercostal access or nephrostomy tube insertion between study arms in any trial. Conclusions: While greater analgesic use with GA alone likely minimizes or obscures differences in patient-reported pain scores, PNBs may offer a significant opioid-sparing analgesic effect during postoperative recovery after PCNL.


Sujet(s)
Néphrolithotomie percutanée , Bloc nerveux , Analgésiques , Analgésiques morphiniques , Humains , Bloc nerveux/méthodes , Douleur postopératoire/traitement médicamenteux , Nerfs périphériques
9.
Eur Urol Focus ; 8(5): 1461-1468, 2022 09.
Article de Anglais | MEDLINE | ID: mdl-34836838

RÉSUMÉ

BACKGROUND: Retrograde intrarenal surgery (RIRS) has become the preferred treatment modality for nephrolithiasis. However, because of ongoing uncertainties regarding the optimal perioperative management, operative technique, and postoperative follow-up, as well as a lack of standardization for outcome reporting, consensus is needed to achieve more uniform clinical practice worldwide. OBJECTIVE: To develop recommendations for RIRS on the basis of existing data and expert consensus. DESIGN, SETTING, AND PARTICIPANTS: A protocol-driven, three-phase study was conducted by the European Association of Urology Section of Urolithiasis (EULIS) and the International Alliance of Urolithiasis (IAU). The process included: (1) a nonsystematic review of the literature to define domains for discussion; (2) a two-round modified Delphi survey involving experts in this field; and (3) an additional group meeting and third-round survey involving 64 senior representative members to formulate the final conclusions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The results from each previous round were returned to the participants for re-evaluation of their decisions during the next round. The agreement threshold was set at 70%. RESULTS AND LIMITATIONS: The panel included 209 participants who developed 29 consensus statements on the following topics of interest: (1) perioperative infection management; (2) perioperative antithrombotic therapy; (3) fundamentals of the operative technique; and (4) standardized outcome reporting. Although this consensus can be considered as a useful reference for more clinically oriented daily practice, we also acknowledge that a higher level of evidence from further clinical trials is needed. CONCLUSIONS: The consensus statements aim to guide and standardize clinical practice and research on RIRS and to recommend standardized outcome reporting. PATIENT SUMMARY: An international consensus on the best practice for minimally invasive surgery for kidney stones was organized and developed by two international societies. It is anticipated that this consensus will provide further guidance to urologists and may help to improve clinical outcomes for patients.


Sujet(s)
Calculs rénaux , Urolithiase , Urologie , Humains , Urologie/méthodes , Calculs rénaux/chirurgie , Urolithiase/chirurgie , Consensus , Interventions chirurgicales mini-invasives
10.
Int. braz. j. urol ; 47(5): 957-968, Sept.-Oct. 2021. tab
Article de Anglais | LILACS | ID: biblio-1286806

RÉSUMÉ

ABSTRACT The presence of lower pole stones poses a unique challenge due to the anatomical considerations involved in their management and treatment. Considerable research has been performed to determine the optimal strategy when faced with this highly relevant clinical scenario. Standard options for management include observation, shock wave lithotripsy, retrograde intrarenal surgery, or percutaneous nephrolithotomy. Indeed, each approach confers a distinct set of risks and benefits, which must be placed into the context of patient preference and expected outcomes. The current state of practice reflects a combination of lessons learned from managing calculi not only in the lower pole, but also from other locations within the kidney as well.


Sujet(s)
Humains , Néphrostomie percutanée , Lithotritie , Calculs rénaux/chirurgie , Néphrolithotomie percutanée
11.
J Endourol ; 35(12): 1838-1843, 2021 12.
Article de Anglais | MEDLINE | ID: mdl-34107778

RÉSUMÉ

Introduction: Procedure-specific guidelines for postsurgical opioid use can decrease overprescribing and facilitate opioid stewardship. Initial recommendations were based on feasibility data from limited pilot studies. This study aims to refine opioid prescribing recommendations for endourological and minimally invasive urological procedures by integrating emerging clinical evidence with a panel consensus. Materials and Methods: A multistakeholder panel was convened with broad subspecialty expertise. Primary literature on opioid prescribing after 16 urological procedures was systematically assessed. Using a modified Delphi technique, the panel reviewed and revised procedure-specific recommendations and opioid stewardship strategies based on additional evidence. All recommendations were developed for opioid-naive adult patients after uncomplicated procedures. Results: Seven relevant studies on postsurgical opioid prescribing were identified: four studies on ureteroscopy, two studies on robotic prostatectomy including a combined study on robotic nephrectomy, and one study on transurethral prostate surgery. The panel affirmed prescribing ranges to allow tailoring quantities to anticipated need. The panel noted that zero opioid tablets would be potentially appropriate for all procedures. Following evidence review, the panel reduced the maximum recommended quantities for 11 of the 16 procedures; the other 5 procedures were unchanged. Opioids were no longer recommended following diagnostic endoscopy and transurethral resection procedures. Finally, data on prescribing decisions supported expanded stewardship strategies for first-time prescribing and ongoing quality improvement. Conclusion: Reductions in initial opioid prescribing recommendations are supported by evidence for most endourological and minimally invasive urological procedures. Shared decision-making before prescribing and periodic reevaluation of individual prescribing patterns are strongly recommended to strengthen opioid stewardship.


Sujet(s)
Analgésiques morphiniques , Troubles liés aux opiacés , Adulte , Analgésiques morphiniques/usage thérapeutique , Humains , Mâle , Interventions chirurgicales mini-invasives , Douleur postopératoire/traitement médicamenteux , Types de pratiques des médecins
12.
World J Urol ; 39(11): 4275-4281, 2021 Nov.
Article de Anglais | MEDLINE | ID: mdl-34019137

RÉSUMÉ

PURPOSE: To evaluate the total cost of outpatient flexible cystoscopy associated with reusable device purchase, maintenance, and reprocessing, and to assess potential cost benefits of single-use flexible cystoscopes. METHODS: Cost data regarding the purchasing, maintaining, and reprocessing of reusable flexible cystoscopes were collected using a micro-costing approach at a high-volume outpatient urology clinic. We estimated the costs to facilities with a range of annual procedure volumes (1000-3000) performed with a fleet of cystoscopes ranging from 10 to 25. We also compared the total cost per double-J ureteral stent removal procedure performed using single-use flexible cystoscopes versus reusable devices. RESULTS: The cost associated with reusable flexible cystoscopes ranged from $105 to $224 per procedure depending on the annual procedure volume and cystoscopes available. As a practice became more efficient by increasing the ratio of procedures performed to cystoscopes in the fleet, the proportion of the total cost due to cystoscope reprocessing increased from 22 to 46%. For ureteral stent removal procedures, the total cost per procedure using reusable cystoscopes (range $165-$1469) was higher than that using single-use devices ($244-$420), unless the annual procedure volume was sufficiently high relative to the number of reusable cystoscopes in the fleet (≥ 350 for a practice with ten reusable cystoscopes, ≥ 700 for one with 20 devices). CONCLUSION: The cost of reprocessing reusable cystoscopes represents a large fraction of the total cost per procedure, especially for high-volume facilities. It may be economical to adopt single-use cystoscopes specifically for stent removal procedures, especially for lower-volume facilities.


Sujet(s)
Coûts et analyse des coûts , Cystoscopes/économie , Cystoscopie/économie , Cystoscopie/instrumentation , Matériel jetable/économie , Procédures de chirurgie ambulatoire , Conception d'appareillage , Humains
13.
Int Braz J Urol ; 47(5): 957-968, 2021.
Article de Anglais | MEDLINE | ID: mdl-33861542

RÉSUMÉ

The presence of lower pole stones poses a unique challenge due to the anatomical considerations involved in their management and treatment. Considerable research has been performed to determine the optimal strategy when faced with this highly relevant clinical scenario. Standard options for management include observation, shock wave lithotripsy, retrograde intrarenal surgery, or percutaneous nephrolithotomy. Indeed, each approach confers a distinct set of risks and benefits, which must be placed into the context of patient preference and expected outcomes. The current state of practice reflects a combination of lessons learned from managing calculi not only in the lower pole, but also from other locations within the kidney as well.


Sujet(s)
Calculs rénaux , Lithotritie , Néphrolithotomie percutanée , Néphrostomie percutanée , Humains , Calculs rénaux/chirurgie
15.
J Urol ; 205(6): 1718-1724, 2021 06.
Article de Anglais | MEDLINE | ID: mdl-33605795

RÉSUMÉ

PURPOSE: Urinary incontinence is frequently underreported and underdiagnosed in the clinical setting. We analyzed 12 years of data from a large, nationally representative sample of women in the United States to assess the prevalence, severity, and daily impact of urinary incontinence and its subtypes at the population level. MATERIALS AND METHODS: We analyzed data from 15,003 women aged ≥20 years who participated in the 2005-2016 National Health and Nutrition Examination Survey. We estimated the prevalence of urinary incontinence in the prior year, overall and by subtype (stress, urgency or mixed). Among women with urinary incontinence, we additionally assessed symptom severity using the validated 4-level Incontinence Severity Index, as well as impact on daily activities. RESULTS: The 2005-2016 prevalence of any urinary incontinence was 53%; 16% of women had mixed urinary incontinence, 26% had stress only and 10% had urgency only. While urgency urinary incontinence and mixed urinary incontinence were highest among women aged ≥60 years, stress urinary incontinence was highest among women aged 40-59 years. NonHispanic Black women had higher prevalence of urgency urinary incontinence and lower prevalence of stress urinary incontinence compared to other racial/ethnic groups. Of women with urinary incontinence, 30% reported moderate or severe symptoms, which were more common among older than younger women. In addition, 24% of women with urinary incontinence reported that the condition affected their daily activities. CONCLUSIONS: Our study demonstrates a high prevalence of urinary incontinence among a nationally representative population of women in the United States, with many reporting that urinary incontinence affected their daily activities. Age and racial/ethnic trends varied by urinary incontinence subtype.


Sujet(s)
Incontinence urinaire/épidémiologie , Activités de la vie quotidienne , Adulte , Études transversales , Femelle , Humains , Adulte d'âge moyen , Prévalence , Indice de gravité de la maladie , Facteurs temps , États-Unis/épidémiologie , Jeune adulte
16.
Nat Rev Urol ; 18(3): 160-169, 2021 03.
Article de Anglais | MEDLINE | ID: mdl-33432182

RÉSUMÉ

Poor ergonomics in the operating room can have detrimental effects on a surgeon's physical, psychological and economic well-being. This problem is of particular importance to urologists who are trained in nearly all operative approaches (open, laparoscopic, robotic-assisted, microscopic and endoscopic surgery), each with their own ergonomic considerations. The vast majority of urologists have experienced work-related musculoskeletal pain or injury at some point in their career, which can result in leaves of absence, medical and/or surgical treatment, burnout, changes of specialty and even early retirement. Surgical ergonomics in urology has been understudied and underemphasized. In this Review, we characterize the burden of musculoskeletal injury in urologists and focus on various ergonomic considerations relevant to the urology surgeon. Although the strength of evidence remains limited in this space, we highlight several practical recommendations stratified by operative approach that can be incorporated into practice without interrupting workflow whilst minimizing injury to the surgeon. These recommendations might also serve as the foundation for ergonomics training curricula in residency and continuing medical education programmes. With improved awareness of ergonomic principles and the sequelae of injury related to urological surgery, urologists can be more mindful of their operating room environment and identify ways of reducing their own symptoms and risk of injury.


Sujet(s)
Ingénierie humaine , Douleur musculosquelettique/prévention et contrôle , Blessures professionnelles/prévention et contrôle , Procédures de chirurgie urologique , Urologues , Cystoscopie , Humains , Laparoscopie , Microchirurgie , Interventions chirurgicales robotisées , Urétéroscopie
17.
Prostate Cancer Prostatic Dis ; 24(1): 106-113, 2021 03.
Article de Anglais | MEDLINE | ID: mdl-32513968

RÉSUMÉ

BACKGROUND: Clinical guidelines have conflicting recommendations on the role of prostate artery embolization (PAE), a novel interventional radiology technique used to treat benign prostatic hyperplasia (BPH). In the absence of consensus among clinicians, patients may seek information online, where consumer-targeted content has proliferated in recent years. Our objective was to assess the content and quality of online information about prostate artery embolization (PAE). METHODS: We evaluated patient interest and exposure to PAE by searching Google Trends for PAE and searching Google for BPH and treatment-related terms. To assess online content about PAE safety and efficacy, we queried Google for patient-oriented websites and YouTube for consumer videos, assessing quality using the validated DISCERN instrument and performing an evidence-based content analysis of how indications, risks, and benefits of PAE were presented. RESULTS: Worldwide searches for PAE peaked in 2019; PAE was mentioned in 15 (26%) of the 57 general BPH-related websites. From our PAE-specific searches, we identified 50 websites and 31 videos. Academic hospitals were the most common sponsor of both PAE-related websites (16, 32%) and videos (15, 48%). Among sources offering PAE to patients, only 15% of websites and 11% of videos explicitly did so as part of a clinical trial. The average DISCERN rating of quality of content was 3.0 out of 5 for websites and 2.0 out of 5 for videos (p < 0.001). Over a quarter of websites and more than half of videos contained potential misinformation, inaccuracies, or non-evidence-based claims about PAE (p = 0.02). CONCLUSIONS: Online consumer information about PAE is of low to moderate quality, with a high frequency of non-evidence-based claims. In the absence of guideline consensus about the role of PAE, clinicians should offer shared decision making and evidence-based counseling about the risks and benefits of PAE.


Sujet(s)
Embolisation thérapeutique/méthodes , Internet , Prostate/vascularisation , Hyperplasie de la prostate/thérapie , Sujet âgé , Artères , Études de suivi , Humains , Injections artérielles , Mâle , Études rétrospectives , Facteurs temps , Résultat thérapeutique
18.
BJU Int ; 127(2): 247-253, 2021 02.
Article de Anglais | MEDLINE | ID: mdl-32805761

RÉSUMÉ

OBJECTIVE: To assess the quality and accuracy of online videos about the medical management of nephrolithiasis. MATERIALS AND METHODS: To evaluate trends in online interest, we first examined the frequency of worldwide YouTube searches for 'kidney stones' from 2015 to 2020. We then queried YouTube with terms related to symptoms and treatment of kidney stones and analysed English-language videos with >5000 views. Quality was assessed using the validated DISCERN instrument. Evidence-based content analysis of video content and viewer comments was performed. RESULTS: Online searches for videos about kidney stones doubled between 2015 and 2019 (P < 0.001). We analysed 102 videos with a median (range) number of views of 46 539 (5024-3 631 322). The mean (sd) DISCERN score was 3.0 (1.4) out of 5, indicating 'moderate' quality; scores were significantly higher for the 21 videos (21%) authored by academic hospitals (mean 3.7 vs 2.8, P = 0.02). Inaccurate or non-evidence-based claims were identified in 23 videos (23%); none of the videos authored by academic institutions contained inaccurate claims. Videos with inaccurate statements had more than double the viewer engagement (viewer-generated comments, 'thumbs up' and 'thumbs down' ratings) compared to videos without inaccuracies (P < 0.001). Among viewer comments, 43 videos (43%) included comments with inaccurate or non-evidence-based claims, and a large majority (82 videos, 80%) had 'chatbot' recommendations. CONCLUSIONS: Interest in YouTube videos about nephrolithiasis has doubled since 2015. While highly viewed videos vary widely in quality and accuracy, videos produced by academic hospitals have significantly fewer inaccurate claims. Given the high prevalence of stone disease and poor-quality videos, patients should be directed to evidence-based content online.


Sujet(s)
Diffusion de l'information/méthodes , Calculs rénaux/diagnostic , Médias sociaux/normes , Enregistrement sur magnétoscope/normes , Humains , Reproductibilité des résultats
19.
Urology ; 150: 86-91, 2021 04.
Article de Anglais | MEDLINE | ID: mdl-33296698

RÉSUMÉ

OBJECTIVE: To examine US trends in neuromodulation for urinary incontinence (UI) treatment from 2004 to 2013. METHODS: This study utilized 2 data sources: the Optum© de-identified Clinformatics® Data Mart Database for privately insured adults aged 18-64 years with a UI diagnosis (N≈40,000 women and men annually) and the Medicare 5% Sample for beneficiaries aged ≥65 years with a UI diagnosis (N≈65,000 women and men annually). We created annual cross-sectional cohorts and assessed prevalence of UI-related neuromodulation procedures among men and women separately from 2004 to 2013. Analyses were conducted overall and stratified by age, race/ethnicity, and geographic region. RESULTS: Nearly all neuromodulation procedures occurred in outpatient settings. Sacral neuromodulation (SNM) procedures for UI in both women and men grew steadily from 2004 to 2013, with more procedures performed in women than men. Among women with UI, SNM prevalence grew from 0.1%-0.2% in 2004 to 0.5%-0.6% in 2013. Posterior tibial nerve stimulation (PTNS) experienced growth from 2011 to 2013. Chemodenervation of the bladder with onabotulinumtoxinA (BTX) combined with other injectable procedures (including urethral bulking) remained stable over time. CONCLUSIONS: From 2004 to 2013, SNM procedures remained relatively uncommon but increased consistently. PTNS experienced growth starting in 2011 when PTNS-specific insurance claims became available. BTX trends remain unclear; future studies should assess it separately from other injectable procedures. Neuromodulation has a growing role in UI treatment, and ongoing trends will be important to examine.


Sujet(s)
Toxines botuliniques de type A/administration et posologie , Bloc nerveux/tendances , Neurostimulation électrique transcutanée/tendances , Incontinence urinaire/thérapie , Adolescent , Adulte , Sujet âgé , Études transversales , Femelle , Humains , Études longitudinales , Mâle , Medicare (USA)/économie , Medicare (USA)/statistiques et données numériques , Adulte d'âge moyen , Bloc nerveux/économie , Bloc nerveux/méthodes , Bloc nerveux/statistiques et données numériques , Plancher pelvien/innervation , Plancher pelvien/physiopathologie , Neurostimulation électrique transcutanée/économie , Neurostimulation électrique transcutanée/statistiques et données numériques , États-Unis , Vessie urinaire/innervation , Vessie urinaire/physiopathologie , Incontinence urinaire/économie , Jeune adulte
20.
J Endourol ; 35(7): 1058-1066, 2021 07.
Article de Anglais | MEDLINE | ID: mdl-33213184

RÉSUMÉ

Objective: The aim of this study was to comprehensively evaluate the quality of patient-oriented, mobile health applications (apps) available for medical management of kidney stone disease (KSD). Materials and Methods: A systematic search was performed to identify apps from the Apple and Google Play app stores. Eligible apps were divided into two categories: (1) fluid apps and (2) dietary apps. Descriptive characteristics were summarized and app quality was independently evaluated on the basis of technical quality, usability, clinical value, and privacy/security. The validated Mobile App Rating Scale (MARS) was the backbone for the evaluation framework. Results: In total, 31 apps (18 fluid apps and 13 dietary apps) were included. Fluid apps outscore dietary apps in all dimensions of MARS quality. All but one fluid app exceeded the minimum acceptable MARS score of 3.0 vs 46% of dietary management apps. Dietary apps feature less functionality and most are limited to noninteractive informational content. While most data-capturing apps provide a privacy policy and ensure that security measures are taken to protect user identity, only 36% offer users choice or consent for secondary use of their data after data have already been collected. Overall, only one app has undergone any form of real-world clinical investigation. Conclusions: Fluid management apps outperform dietary apps in technical quality, usability, and clinical value at the cost of greater privacy/security risks. Despite not being targeted to patients with KSD, they are higher in most quality measures and offer greater functionality to support long-term disease management compared with dietary apps.


Sujet(s)
Calculs rénaux , Applications mobiles , Prestations des soins de santé , Humains , Calculs rénaux/thérapie , Ordiphone
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...